/stocks — the workspaceLOADING
All TECXSEC filings, by type → · Earnings date & implied move · Search inside filings
Tectonic Therapeutic, Inc. (TECX) is a biological products, (no diagnostic substances) company. 8 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-05 from TECX's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind TECX’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from TECX’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
Not reported in XBRL for this filer.
A plain-English read on TECX plus an auto-SWOT — built from TECX's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate TECX using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Has TECX been issuing shares? Offering history →
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
No lawmaker has disclosed a trade in TECX under the STOCK Act.
No tracked institution reported a position in TECX in the latest 13F round.
Projected from TECX's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentTECX files or announces.
TECX's earnings reaction has been evenly split — 4 up, 4 down across its last 8 reports.
Each figure is one earnings reaction — how much TECX moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Earnings reactions have been moderate.
The average is inflated by its most volatile prints (+17.5% and -3.7%).
A more typical earnings reaction has been approximately ±3.6%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-06 | +4.8% |
| 2026-05-07 | -0.1% |
| 2026-02-26 | +1.5% |
| 2025-11-06 | +17.5% |
| 2025-08-07 | -3.7% |
| 2025-05-08 | +4.2% |
| 2025-03-20 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -3.5% |
| 2024-11-07 | -2.0% |
| McNamara PeterChief Scientific Officer | SELL | $6K | view → |
| Ruddy Marcella K.Chief Medical Officer | SELL | $32K | view → |
| Ruddy Marcella K.Chief Medical Officer | SELL | $31K | view → |
| McNamara PeterChief Scientific Officer | SELL | $189K | view → |
| Ruddy Marcella K.Chief Medical Officer | SELL | $300K | view → |
| McNamara PeterChief Scientific Officer | SELL | $78K | view → |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.